Cannabis-derived compounds show promise in reducing agitation in advanced dementia patients

A Phase 2 clinical trial, presented at the International Alzheimer's Association Conference (AAIC 2026) in London, has demonstrated that a combination of THC (tetrahydrocannabinol) and CBD (cannabidiol) significantly reduced agitation in individuals with advanced stages of Alzheimer's and other dementias. The study, named LiBBY (Life’s End Benefits of cannaBidiol and tetrahYdrocannabinol), involved 120 participants with clinically relevant agitation, who received an oral formulation of 2 mg THC and 100 mg CBD twice daily. The trial was multicentric, randomized, double-blind, and placebo-controlled, considered a robust standard for medical research. Results showed that participants receiving the THC/CBD combination experienced a rapid and sustained reduction in agitation scores. By week 2, the treated group showed a 6.27-point greater reduction in agitation scores compared to placebo, and by week 12, this difference increased to 8.23 points. Furthermore, physician-assessed global improvement was notably higher in the THC/CBD group, with 83.9% showing improvement at week 2 and 87.2% at week 12, compared to 30.5% and 23.6% in the placebo group, respectively. Agitation affects approximately half of individuals with dementia near the end of life and can manifest as repetitive behaviors, vocalizations, or physical aggression, often signaling unmet needs or discomfort. This new therapeutic approach offers potential for a more humane and dignified experience for patients and their families during a vulnerable time, as current treatments like benzodiazepines and antipsychotics carry significant risks. Separately, the Alzheimer's Association also announced the launch of the $100 million PROTECT-Cog study, a global trial investigating whether combining lifestyle interventions with GLP-1 receptor agonist medications can further reduce the risk of cognitive decline, mild cognitive impairment, and dementia in older adults.